ReviewParkinson's disease2017
Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.
Review in Parkinson's disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Lorazepam-induced full resolution of catatonia and psychosis in Parkinson's disease with acromegaly: a case report.Frontiers in psychiatry · 2026Article
- Treatment of Parkinson's Disease-Related Psychosis.Clinical pharmacology : advances and applications · 2026Review
- Narrative Medicine, Dementia, and Alzheimer's Disease: A Scoping Review.Healthcare (Basel, Switzerland) · 2025Review
- Antipsychotics for Parkinson's disease: a protocol for a systematic review with network meta-analysis and trial sequential analysis.BMJ open · 2025Article
- The Impact of Integrating a Parkinson's Specialist Psychiatrist Into the Multidisciplinary Team on Patients With Parkinson's and Cognitive Impairment.Parkinson's disease · 2025Article
- Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review.Journal of the Chinese Medical Association : JCMA · 2024Review
- Review
- Combined Pimavanserin and Maintenance Electroconvulsive Therapy: A Novel Approach to Parkinson's Disease Psychosis.Cureus · 2024Article
- On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.CNS drugs · 2024Article
- How to Use the New European Academy of Neurology/Movement Disorder Society European Section Guideline for Invasive Therapies in Parkinson's Disease.Movement disorders clinical practice · 2024Review
- Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis.Clinical parkinsonism & related disorders · 2024Review
- Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.Neurology and therapy · 2022Article
- Review
- Economic Evaluation of Healthcare Resource Utilization and Costs for Newly Diagnosed Dementia-Related Psychosis.Geriatrics (Basel, Switzerland) · 2022Article
- Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?BMC neurology · 2021Article
- QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.Neuropsychiatric disease and treatment · 2021Review
- High frequency of psychosis in late-stage Parkinsońs disease.Clinical parkinsonism & related disorders · 2021Article
- Increased risk of falls and fractures in patients with psychosis and Parkinson disease.PloS one · 2021Article
- G-CSF mediated neutrophil augmentation in a unique case of comorbid idiopathic Parkinson's disease and treatment-resistant schizophrenia on clozapine.Therapeutic advances in psychopharmacology · 2020Article
- A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey.Frontiers in psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Investigation into neuropsychiatric symptoms in Parkinson's disease (PD) is sparse and current drug development is mainly focused on the motor aspect of PD. The tight association of psychosis with an impaired quality of life in PD, together with an important underreporting of this comorbid condition, contributes to its actual insufficient assessment and management. Furthermore, the withdrawal from access to readily available treatment interventions is unacceptable and has an impact on PD prognosis. Despite its impact, to date no standardized guidelines to the adequate management of PD psychosis are available and they are therefore highly needed. Readily available knowledge on distinct clinical features as well as early biomarkers of psychosis in PD justifies the potential for its timely diagnosis and for early intervention strategies. Also, its specific characterisation opens up the possibility of further understanding the underlying pathophysiological mechanisms giving rise to more targeted therapeutic developments in the nearer future. A literature review on the most recent knowledge with special focus on specific clinical subtypes and pathophysiological mechanisms will not only contribute to an up to date practical approach of this condition for the health care providers, but furthermore open up new ideas for research in the near future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.